This is a working overview of growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-08. Anything still debated is marked as such rather than presented as settled.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
==== Pyrrolidine compounds ==== The pyrrolidine type of DPP-4 inhibitors was first discovered after HTS. Research showed that the pyrrolidine rings were the part of the compounds that fit into the binding site. Further development has led to fluoro substituted pyrrolidines that show superior activity, as well as pyrrolidines with fused cyclopropylrings that are highly active.
==== Species ==== The genus includes dog violets, a group of scentless species which are the most common Viola in many areas, sweet violet (Viola odorata) (named from its sweet scent), and many other species whose common name includes the word "violet". But not other "violets": Neither Streptocarpus sect. Saintpaulia ("African violets", Gesneriaceae) nor Erythronium dens-canis ("dogtooth violets", Liliaceae) are related to Viola.
(CH3)2CHC(O)CO2− + CH2O → HOCH2(CH3)2CC(O)CO2− This conversion is catalyzed by ketopantoate hydroxymethyltransferase. Like many α-ketoacids, α-ketoisovaleric acid is prone to decarboxylation to give isobutyraldehyde:
Sources: en.wikipedia.org
== Mechanism of action == In biochemical studies of mitochondria, the effect of atractyloside on the ADP/ATP transport was recognized even before the actual transporter was identified. ATR or CATR bind to the ADP/ATP translocase, which is located on the inner mitochondrial membrane. ATR binds competitively to the translocase competitive up to a concentration of 5 mmol while CATR binds in a non-competitive manner. As a result, the exchange of ADP and ATP is no longer carried out and the cell dies due to lack of energy. The chemical structure and charge distribution of atractyloside is similar to that of ADP: the sulfate groups correspond to the phosphate groups, the glucose part corresponds to the ribose part, and the hydrophobic atractyligenine residue corresponds to the hydrophobic purine residue of ADP. The carboxyl group on the C4 atom of the atractyligenin is important for toxicity. If this is reduced to a hydroxyl group (atractylitriol), the substance becomes non-toxic. Modification of any of the sulfate groups renders the compound non-toxic. On the other hand, the free hydroxy group on the C6 atom of the glucose moiety can be modified without loss of compound potency.
Mohammad Bagher Ghalibaf – Speaker of the Parliament (head of delegation) Abbas Araghchi – Foreign Minister Reza Amiri Moghadam – Ambassador to Pakistan Ali Akbar Ahmadian – Member of the Supreme National Security Council Ali Bagheri Kani – Deputy to the Supreme National Security Council Esmail Ahmadi Moghadam – President of the National Defence University Mohammad Jafari – Assistant to the Secretary at the Supreme National Security Council Abdolnaser Hemmati – Central Bank Governor Kazem Gharibabadi – Deputy Foreign Minister Majid Takht-Ravanchi – Deputy Foreign Minister Valiollah Nouri – Deputy Foreign Minister Esmail Baghaei – Deputy Foreign Minister and Foreign Ministry spokesperson Abolfazl Amouei – Member of Parliament Mohammad Nabavian – Member of Parliament Pakistani leadership, including Prime Minister Shehbaz Sharif, Foreign Minister Ishaq Dar and Chief of Defense Forces Asim Munir, facilitated the negotiations and acted as intermediaries. On 11 April, it was reported that amid the negotiations, high-ranking senior IRGC officials arrived in Pakistan to provide "consultation" to the Iranian delegation.
Theranos claimed to have data verifying the accuracy and reliability of its tests that would be published. In February 2016, Theranos announced that it would permit the Cleveland Clinic to complete a validation study of its technology. In March 2016, a study authored by 13 scientists appeared in the Journal of Clinical Investigation, where it was stated that the company's blood test results were flagged "outside their normal range 1.6× more often than other testing services", that 68 percent of lab measurements evaluated "showed significant interservice variability", and that "lipid panel test results between Theranos and other clinical services" were "nonequivalent". In August 2016, the company introduced a new robotic capillary blood testing unit named "miniLab" at the 2016 annual meeting of the American Association for Clinical Chemistry, but did not present any data supporting the claimed abilities of the device. The miniLab was allegedly capable of carrying out a range of tests from a small amount of blood. After Theranos failed to address concerns that it exaggerated the capabilities of the miniLab, Walgreens withdrew from their partnership. It was later revealed that Theranos had voided two years of test results showing inaccuracies with the Edison technology.
Sources: en.wikipedia.org
=== Center of Excellence for Transgender Health (UCSF) === The Center of Excellence for Transgender Health at the University of California, San Francisco was established in 2009, dedicated to improving health equity for trans and gender nonconforming communities. The Center of Excellence for Transgender Health is a national advisory board composed of transgender leaders from across the United States, bringing expertise in the research of transgender health. Guidelines for Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People contains guidelines developed by The Center of Excellence for Transgender Health that are widely used clinical guidelines for transgender healthcare.
=== Australia === Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura mater grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.
B&O Supprettes is the brand name for a prescription medication containing powdered opium and belladonna alkaloids in a suppository form. They are indicated for the treatment of moderate to severe pain from urethral spasm, and for extending the interval(s) between injections of opiates. The drug has various "off label" uses, including renal colic, intestinal cramps, tenesmus and diarrhea. They are also often prescribed after urinary bladder surgery. B&O Supprettes was unique in the United States because they were the only drug containing opium that is for suppository use sold in the US and, in fact, one of the very few medications that contains opium in any form in the US along with paregoric and opium tincture (laudanum).
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.